Rhythm Pharmaceuticals, Inc. (RYTM) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Boston, MA, United States. Le PDG actuel est David Meeker.
RYTM a date d'introduction en bourse 2017-10-09, 283 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $5.96B.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development and commercialization of therapeutics for rare genetic diseases of obesity. The company's lead product, IMCIVREE, is a melanocortin-4 receptor agonist approved for treating obesity caused by POMC, PCSK1, and LEPR deficiencies, as well as Bardet-Biedl and Alström syndromes. Rhythm is also advancing setmelanotide through Phase II clinical trials for multiple rare genetic obesity indications, including heterozygous POMC or LEPR deficiency, SH2B1 deficiency, MC4 receptor deficiency, and Smith-Magenis syndrome. Founded in 2008 and formerly known as Rhythm Metabolic, Inc., the company collaborates with leading clinical research organizations to advance its pipeline and address significant unmet medical needs in rare genetic obesity.
